Compare Biogen Inc (BIIB) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs KLA Corp. — how do they compare? Biogen Inc trades at $206.24 (market cap $30.13B), while KLA Corp. trades at $207.46 (market cap $261.92B). The key difference: KLA Corp. is far larger — about 8.7× Biogen Inc's market cap, and KLA Corp. pays a 0.46% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | KLAC | |
|---|---|---|
Market Cap | $30.13B | $261.92B |
Sector | Health | Technology |
52-Week High | $216.63 | $301.71 |
52-Week Low | $128.93 | $84.39 |
Enterprise Value | $37.20B | $263.17B |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
KLA Corporation (KLAC) trades at $192.74, down 2.71% on the day, amid a broader semiconductor sector pullback. The stock shows strong fundamentals with revenue growth to $12.16B in 2025 and net income of $4.06B, though valuation ratios remain elevated with a P/E of 54.77. Recent corporate actions include a 1:10 stock split and dividend declarations, while technical indicators signal near-term bearish pressure with key support at $189.
KLAC presents a compelling long-term investment case driven by AI-driven semiconductor equipment demand and consistent earnings beats, but faces risks from high valuation and sector volatility. Analyst consensus remains bullish with a $246.93 price target implying 28% upside, though investors should monitor execution against growth expectations and competitive dynamics in the semiconductor equipment space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
